Korea NK/T-Cell Lymphoma CCRT (Kim)

Background

Korean retrospective multicenter analysis of concurrent chemoradiotherapy (CCRT) vs sequential chemotherapy for stage I–II extranodal nasal-type NK/T-cell lymphoma. One of the key studies supporting RT-inclusive treatment strategies for NK/T-cell lymphoma, which is radiation-sensitive but chemotherapy-resistant (due to P-glycoprotein overexpression).

Interventions and follow up

Arm A: CCRT — DeVIC or VIPD regimen concurrent with RT 40–52.8 Gy
Arm B: Sequential CHOP chemotherapy followed by RT or RT alone
Primary endpoint: Overall survival and progression-free survival
mFollow up: Not specified

Results

5-yr OS (CCRT): ~67%
5-yr OS (CHOP-based): ~39%
CR rate (CCRT): ~80–85%
CR rate (CHOP-based): ~50–60%

Adverse events

Main adverse events: Grade 3–4 neutropenia common with CCRT. Mucositis grade 3 in ~30%. Treatment delay required in some patients due to toxicity.

Conclusions

CCRT achieves significantly higher CR rates and improved OS compared with CHOP-based chemotherapy alone or sequential approaches for stage I–II NK/T-cell lymphoma. RT-containing regimens are essential for this radiation-sensitive but anthracycline-resistant disease.

Key Limitations

Key Limitations: Retrospective analysis with non-randomized treatment allocation. Significant heterogeneity in chemotherapy regimens across study groups. CHOP is now known to be inferior to L-asparaginase-based regimens (SMILE, P-GEMOX) for NK/T-cell lymphoma; CCRT comparisons using modern regimens would be more relevant.

Clinical Context

NK/T-cell lymphoma is exquisitely radiosensitive but resistant to CHOP-based chemotherapy due to MDR1 overexpression. Current NCCN guidelines recommend L-asparaginase-based CCRT (SMILE/VIPD + RT ≥50 Gy) for stage I–II NK/T-cell lymphoma. This Korean series provided important early evidence supporting RT-inclusive strategies in this rare lymphoma.

References

References: Kim SJ et al, JCO 2009 (Korea NK/T-cell)